logo sanofi
logo sanofi


Atopic dermatitis (AD) is a chronic, inflammatory skin disease.

Only by looking beneath the surface can we start to truly understand it.


Looks can be deceiving

Current evidence suggests that in AD, non-lesional, or normal-looking atopic skin isn’t ‘normal’ skin.1,2

Systemic, sub-clinical inflammation, skin barrier dysfunction and immunologic abnormalities are continuously present which underlines the chronic and persistent nature of the disease and its signs and symptoms.2–4

Underlying inflammation and an endless cycle of itching and lesions

Underlying chronic inflammation is a source of lesions and itch: the primary signs and symptoms of AD.1,2 This underlying inflammation involves interleukins which act as inflammatory mediators in the process.2

Patients with severe AD often suffer from a cycle of frequent, unpredictable flares that may last days or weeks and which can involve persistent itching and lesions.3,4

Looking beyond episodic control

With a chronic skin condition like AD, patients often need strategies that manage the overall disease course, not just the episodes of severe symptoms.5

Addressing the underlying, persistent inflammation may help to manage the signs and symptoms of AD beyond these periods.1,6

A patient’s burden on all aspects of life

Every day can be a challenge with AD, as it has been shown to have a negative impact on quality of life.7,8

The effects of the condition are pervasive, affecting patients at night, in their careers and their personal relationships, causing shame, stress and even depression. 8, 10–13

Getting under the surface, to the real stories of AD

AD can affect people every day. So this year, for the first ever AD day, we want to highlight the reality of all the days that AD has taken from people and to show those with AD that this day is for them.

Watch or share and we’ll donate!

Help raise awareness about AD and support those who live with the condition every day. Simply watch or share this AD Day video through Facebook or Twitter and Sanofi and Regeneron will donate $1 to the International Alliance of Dermatology Patient Organisations.

Click here for full terms and conditions for the donations. Thank you for your support!


  1. Suárez-Fariñas M et al. J Allergy Clin Immunol 2011; 127(4): 954–964.
  2. Gittler JK et al. J Allergy Clin Immunol 2012; 130(6): 1344–1354.
  3. Gelmetti C and Wollenberg A. Br J Dermatol 2014; 170(suppl 1): 19–24.
  4. Guttman-Yassky E et al. Expert Opin Biol Ther 2013; 13(4): 549–561.
  5. Leung DYM et al. J Clin Invest 2004; 113(5): 651–657.
  6. Bieber T. N Engl J Med 2008; 358(14): 1483–1494.
  7. Simpson EL et al. J Am Acad Dermatol 2016; 74(3): 491–498.
  8. Zuberbier T et al. J Allergy Clin Immunol 2006; 118(1): 226–232.
  9. Fivenson D et al. J Manag Care Pharm 2002; 8(5): 333–342.


  1. Ibler K and Jemec GBE. Dermatol Reports 2011; 3(1): e5.
  2. Holm EA et al. J Eur Acad Dermatol Venereol 2006; 20(3): 255–259.
  3. Misery L et al. Dermatology 2007; 215(2): 123–129.
  4. Dawn A et al. Br J Dermatol 2009; 160(3): 642–644.